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Abstract Healthcare payers make decisions on funding for treatments for diseases, such as chronic-obstructive 
pulmonary disease (COPD), on a population level, so require evidence of treatment success in appropriate populations, 
using usual routine care as the comparison for alternative management approaches. Such health outcomes evidence can 
be obtained from a number of sources. 
The ‘gold standard’ method for obtaining evidence of treatment success is usually taken as the randomized controlled 
prospective clinical triaLYet the value of such studies in providing evidence for decision-makers can be questioned due to 
the restricted entry criteria limiting the ability to generalize to real life populations, narrow focus on individual parameters, 
use of placebo for comparison rather than usual therapy and unrealistic intense monitoring of patients. Evidence obtained 
from retrospective and observational studies can supplement that from randomized clinical trials, providing that care is 
taken to guard against bias and confounders. Howevet; very large numbers of patients must be investigated if small 
differences between drugs and treatment approaches are to be detected. Administrative databases from healthcare 
systems provide an opportunity to obtain observational data on large numbers of patients. Such databases have shown 
that high healthcare costs in patients with COPD are associated with co-morbid conditions and current smoking status, 
Analysis of an administrative database has also shown that elderly patients with COPD who received inhaled 
corticosteroids within 90 days of discharge from hospital had 24% fewer repeat hospitalizations for COPD and were 29% 
less likely to die during the I -year follow-up period. 
In conclusion, there are a number of sources of meaningful evidence of the health outcomes arising from different 
therapeutic approaches that should be of value to healthcare payers making decisions on resource allocation. 
02002 Elsevier Science Ltd 
INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) 
imposes a considerable burden on patients, healthcare 
services and society, yet this is poorly appreciated (I). If 
management of COPD is to be improved, there has to be 
greater recognition of the disease and agreement on 
optimal treatment. Measures of treatment success, as 
defined in management guidelines, tend to focus on the 
perspective of physicians or of patients, with little 
appreciation of the needs of decision-makers for 
appropriate evidence on health outcomes (2,3). This 
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must be addressed if the profile of COPD is to be 
improved, and appropriate levels of resources are to be 
directed at understanding and managing the disease. 
Healthcare payers make decisions on a population 
level, so require evidence of treatment success in 
comparable populations, using usual routine care as the 
comparison for alternative management approaches. As 
COPD cannot be cured, measures of COPD health 
outcomes that are of relevance to healthcare payers 
include ‘symptom-free days’ and ‘exacerbation rates’, as 
well as patient satisfaction and impact on quality of life. 
Use of healthcare resources, particularly hospitalization 
as a result of exacerbations, and the total costs of 
management are also of importance to healthcare payers 
(2). Such health outcomes evidence can be obtained from 
a number of sources. 
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PROSPECTIVE CLINICALTRIALS 
The ‘gold standard’ method for obtaining evidence of 
treatment success is usually taken as the randomized 
controlled prospective clinical trial. Such studies are 
highly valued by those seeking best possible evidence as 
they are designed to test a defined hypothesis in a way 
that reduces bias and controls for confounders, though 
at considerable cost. The results from randomized 
clinical trials often show highly significant differences in 
treatment approaches.Yet the value of these results as 
evidence for decision-makers can be questioned. 
Restricted entry criteria ensure a homogeneous study 
population but limit the ability to generalize to real life 
populations. Tightly controlled conditions that allow 
comparison of one treatment with another may ignore 
other more relevant issues. Using placebo as a 
comparison does not usually reflect normal clinical 
practice. Furthermore, the intense monitoring of patients 
in clinical trials is unreal and may, in itself, bring patient 
benefits, irrespective of the treatment modality being 
evaluated. A clear example of these factors is the 
mortality rate from acute myocardial infarction in studies 
of thrombolytic treatment (7%) which was half that 
usually recorded in cardiac care units (I 2%) (4). 
How do these factors affect clinical trials to obtain 
evidence of treatment success in COPD? This first 
consideration is selection of patients for the trials. 
Definitions of COPD vary between guidelines (I ,3), and 
applying the different criteria may result in very different 
patient populations included in clinical trials. For 
example, the patient population in the EUROSCOP trial 
of inhaled corticosteroids in COPD had an average lung 
function (FEV, 79% predicted) considerably greater than 
that of the population included in the ISOLDE trial of 
corticosteroid use (FEV, 52% predicted) (5,6). Such 
differences in patient population may account for 
differences in study findings. Furthermore, the choice of 
FEV, as the principal characteristic has been questioned - 
asthma is defined physiologically, chronic bronchitis 
clinically and emphysema pathologically, so it is difficult to 
assess COPD only on a measure of lung function. In 
studies on COPD, patients are often entered into the 
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trials only if other conditions can be excluded (Table I), 
raising concerns about the relevance of the study 
findings if they apply only to a small sub-population of 
patients. 
Once the patient population has been defined, there is 
then the issue of defining treatment success. There is 
little agreement on how success in COPD should be 
defined (Table 2) and views of treatment success vary 
with the perspective taken (2). In part, the difficulty in 
defining appropriate measures of treatment success 
stems from a lack of understanding of the disease. It is 
agreed that COPD is a chronic disease with a defined 
pattern (7), but the components of disease pathology 
vary unpredictably. Furthermore, the factors controlling 
susceptibility and the rate of decline are not fully 
established, while the relationship of symptoms to lung 
function (defined by FEV,) also varies unpredictably. 
Once the measures are defined and the results are 
obtained, there is the problem of distinguishing between 
statistically significant results and those that are clinically 
relevant. Furthermore, averaging the findings for the 
population blurs the distinction between those who 
show a good response on the defined criterion and 
those who do not. For example, 60% of patients may 
show improvement in FEV, with inhaled steroids, while 
there is little change in 20% and another 20% actually 
show deterioration in response.The average may suggest 
that all patients should receive the treatment, but it 
could be argued that 40% would be better managed by 
not using the therapy. 
Another difficulty in defining appropriate measures of 
success for assessment in clinical trials is the long-term 
nature of the disease and treatment goals, while clinical 
trials are usually of short duration. In prolonged trials that 
seek to overcome this problem, another difficulty 
emerges - drop-outs from the trialsThese may represent 
a considerable proportion of the original starting 
population. How should these be handled? The reasons 
for dropping out of the study could be highly relevant. 
It seems, therefore, that although the results of 
randomized, prospective clinical trials are highly valued 
by those compiling best evidence of treatment 
approaches, they cannot provide a complete picture of 
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the evidence required by healthcare payers. Clearly, 
alternative approaches to collecting evidence are 
required that seek to address some of the short-comings 
of randomized controlled trials. 
RETROSPECTWE AND 
OBSERVATIONAL STUDIES 
Although the randomized controlled trial is seen as the 
gold standard, probably the best example of high quality 
evidence in the respiratory field is the study that 
demonstrated unequivocally the association between 
smoking and lung cancer (8). In this epidemiological 
surveillance study, around 40 000 doctors were studied 
over a 40-year period. Other surveillance approaches, 
have produced useful evidence of hitherto unsuspected 
drug effects (9). Such naturalistic, observational studies 
do not exclude anyone, so reflect clinical practice more 
closely than the highly selected patient populations 
included in clinical trials, but they also contain more 
potential confounders. They may also take a very long 
time before results are available. A way to address this 
problem is by examining data retrospectively. 
Retrospective studies run the risk of being seen to be 
wise after the event, with bias and the selection of 
favourable cases.As a result, compilers of evidence-based 
guidelines and reviews consider such evidence of lower 
grade than evidence obtained from clinical trials (3) and 
may even exclude it from systematic reviews.Yet it is 
possible to carry out formal structured surveys of 
unselected patient populations and obtain robust 
evidence.An example is an audit that was conducted of 
acute stroke services in the U.K. (I 0). Collecting data 
accurately was identified as of critical importance to the 
robustness of the final results. Consequently, a pilot study 
was carried out to test the reliability of wording used in 
the data collection form. Kappa scores were used to test 
for variability, and the wording modified until data 
collection was accurate. Hospitals throughout the U.K. 
were then surveyed for the proportion of patients with 
acute stroke receiving various assessments and service 
indicators in the time immediately following the event 
and before discharge (e.g. assessment of visual fields, 
ability to swallow, continence care). Feedback was given 
to the hospitals on performance relative to the total 
sample (I I).When repeated a year later, every region in 
the country showed improvement on the provision of 
care for stroke patients (12). Clearly, the evidence 
collected in the first audit had been of sufficient value to 
the recipients that behaviour had changed as a result. 
A similar approach taken to audit COPD care, found 
considerable inter-hospital differences in the proportion 
of patients receiving assessments at initial admission for 
an acute exacerbation (I 3). When the death rate from 
acute exacerbation was examined, a five-fold difference 
was found between hospitals. Small hospitals were found 
to have twice the death rate of large hospitals, possibly 
because of lack of specialist care (14).There was also a 
clear correlation between mortality rate and poor 
performance at initial assessment. Such audit data is an 
essential part of appraisal of clinical practice for 
individuals and units, and forms the basis of action plans 
to improve the delivery of care. 
Another example of a novel approach to supplement 
the information from randomized clinical trials comes 
from an assessment of the leukotriene modifier, 
montelukast in asthma (I 5,I6). Anecdotal reports 
suggested that montelukast was less effective in clinical 
practice than predicted from randomized clinical trials, 
so a study was designed to understand what happens to 
the average patient treated with montelukast., without 
interfering in their management.The approach taken was 
to identify all patients in a practice or clinic who received 
the treatment during the defined time period (February 
1998 - June 2000).This included all those who started 
treatment but stopped for any reason, all ages and grades 
of asthma, and all those with co-morbidities. Patient 
consent was obtained for access to records and to send 
a patient survey form.The only exclusions were patients 
who did not have a diagnosis of asthma, those who had 
received montelukast as part of a clinical trial, and 
patients who were prescribed other leukotriene 
modifiers. Extensive piloting was carried out to ensure 
accuracy in data collection, with modification of data 
collection questions and briefing notes for the 
investigator, until satisfactory levels of inter-observer 
agreement could be demonstrably achieved. 
Although the study was intensive and required 
laborious attention to detail, the results seem robust and 
similar data were obtained from the doctor assessment, 
the external nurse auditors assessment and from the 
patients evaluation. These showed that approximately 
40% of patients experienced significant benefits from the 
treatment (i.e. sufficient to be noticeable by the 
individual), with a similar proportion (40%) showing little 
change in outcomes and 20% (including all drop-outs - 
many of whom should probably not have been given the 
drug at all) experienced worse asthma control. Despite 
the considerable effort required to obtain robust 
evidence, the study cost less to carry out than 
comparable clinical trials. 
Thus retrospective, observational studies can provide 
valuable information on the delivery of care and health 
outcomes in a way that relates directly to routine clinical 
practice. As such, the evidence obtained by these 
methods can supplement that from randomized clinical 
trials, providing that care is taken to guard against bias 
and confounders. However, very large numbers of 
patients must be investigated if small differences between 
drugs and treatment approaches are to be detected. 
With large patient numbers, it is also possible to perform 
subgroup analysis and define, for example, groups of 
patients who show particularly good or particularly poor 
responses. This could allow clinicians and healthcare 
payers to identify those patient groups who could benefit 
most from treatment, and where cost-effectiveness 
analyses can be most favourable. 
OBSERVATIONAL DATABASES 
Observational data may be captured by a variety of 
methods, but commonly it is routinely collected for 
administrative purposes or as part of epidemiological 
surveillance (I 7). Administrative databases are usually 
built primarily for billing purposes, especially in the U.S.A. 
where most healthcare is still proved by the traditional 
fee-for-service systems (e.g. the publicly funded Medicare 
system). However, most countries with nationalized 
healthcare systems and most managed-care systems in 
the U.S.A. also track utilization routinely for auditing 
purposes and for resource allocation decisions. 
Epidemiological surveillance databases (such as cancer 
registries) or public health surveys (such as the National 
Health and Nutrition Examination Survey) may also 
contain utilization data (I 8, I S).Although the information 
from this type of database may be relatively crude or 
incomplete, the enormous size of some of these 
databases provides sufficient power for making 
inferences about health policy. Observational databases 
vary widely in the type and quality of information they 
contain, but they provide the outcomes data required by 
patients, providers and policy makers to inform decisions 
on the management of COPD (Table 3). 
At the Center for Pharmacoeconomic and Outcomes 
Research (CPOR), a large utilization database based on 
administrative data from Lovelace Health Systems has 
been used to examine the costs of healthcare for patients 
with COPD. Lovelace Health Systems operates a regional 
staff-and-network model health maintenance organization 
(HMO) with over 200 000 members. Because Lovelace 
Health Systems also provides traditional fee-for-service 
care, it collects very detailed data on all services. Since 
1987, the CPOR has captured over 2 000 000 patient- 
years of utilization from this HMO. 
One advantage of using a comprehensive database, 
such as that of CPOR, is that it allows the use of case- 
control methods to examine the overall impact of 
specific illnesses on healthcare costs. Many utilization 
studies attempt to estimate disease costs by summing 
costs for hospitalizations, procedures, and drugs that can 
be directly attributed to the disease of interest. This 
approach may underestimate costs because it may miss 
charges in unexpected areas, such laboratory or 
radiology use, and it overlooks the effects a disease may 
have on utilization for other illnesses (20). By matching 
patients with a specific illness to others of the same age 
and gender without the disease, case-control methods 
can describe the impact of a disease on overall costs 
(often referred to as the marginal cost), identify specific 
areas of increased utilization, and also provide a useful 
index comparison against normal expected charges. 
Recently, CPOR completed a case-control analysis of 
COPD costs and utilization among patients treated by 
the Lovelace HMO (2 I). A total of I522 patients with a 
diagnosis of COPD were enrolled in the health plan for 
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COPD patents (Wl522) 
Matched cmlrols (n=4566) 
FIGURE I. Use of outpatient services by patients with COPD and matched controls (2 I), 
the whole of 1997 (i.e. these patients did not die during 
the period or move to another health plan).A matched 
group of 4566 control patients were identified with a 
similar age and gender profile. Medical charts were 
reviewed from 200 COPD cases and 200 controls to 
obtain addition information about smoking histories and 
pulmonary function tests, and to confirm the validity of 
the diagnoses (22). Patients with COPD were more likely 
than the control group to smoke during the study period 
(46.0% vs I3*5%,P < 0.00 I),and of those people who had 
ever smoked, COPD patients had significantly greater 
smoking exposure than those without COPD (49.5 vs 
34.9 pack-years, P=O.O02). On average, patients with 
COPD had 3.7 chronic medical conditions (including 
lung disease), compared with I .8 for the control group 
(P < 0.00 I), particularly heart disease, cancer, 
neurological injuries and gastritis. Just 6% of patients with 
COPD did not have another chronic medical condition. 
Patients with COPD had significantly greater use of 
outpatient services than control cases, with an average of 
27.82 outpatient encounters per patient compared with 
16. I8 for controls (P < 0.001) (2 I). Not surprisingly, 
COPD patients were significantly more likely to use 
respiratory care services; however, increased utilization 
was found in almost all service areas, particularly 
cardiology and emergency services (Fig. I). Although a 
similar proportion of both groups used primary care 
services, the average number of visits made by COPD 
patients was 54% higher than for the controls. Pharmacy 
utilization was significantly greater in COPD patients 
compared with controls (mean prescription fills per 
patient of 35.48 vs 18.42, P C 0.00 I). Only half of the 
increased pharmacy utilization was for respiratory 
medications - significant increases were also found in 
cardiovascular drugs, antibiotics, psychotherapeutic 
drugs and pain medications. Compared with the control 
group, patients with COPD were 2.3 times more likely to 
be admitted to the hospital during the study year, and 
those admitted had significantly more admissions with 
longer average duration of stay (Table 4). Overall, 
healthcare costs among COPD patients were twice 
those of age- and gender-matched controls (Fig. 2) but 
half of COPDf marginal impact would have been lost if 
the analysis had been limited strictly to respiratory 
admissions, treatments, and drugs. 
The CPOR database is being used for additional 
studies designed to determine clinical factors related to 
increased resource utilization. In one study, a total of 302 
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FIGURE 2. Healthcare costs for patlents with COPD and matched controls (2 I ). 
patients with a clinical diagnosis of COPD were 
recruited from the Lovelace Health Plan database (23). 
Touch-screen computers were used to administer 
questionnaires on symptoms and quality of life, and lung 
function was measured before and after a bronchodilator 
and an exercise test. All inpatient and outpatient 
resource utilization data for the I2 months prior to the 
study were obtained. Although only around half of the 
patients had previously received lung function testing, the 
diagnosis of COPD was appropriate for all but 3% of the 
sample, in line with findings from other database studies 
(22). There appeared to be little correlation between 
total annual healthcare costs per patient and the stage of 
COPD, as defined by FEV, (24). However, there was a 
clear correlation between healthcare costs and the 
number of co-morbid conditions, while there was a 
weaker correlation with the activity score on the St 
George’s respiratory questionnaire and incidence of 
wheezing in the previous year. 
In another study using the CPOR database, clinical 
features of 1041 COPD patients treated in I998 were 
used to predict healthcare costs and utilization in 1999 
(25). In multivariate models, a history of oxygen use, any 
hospital admission for COPD, and the presence of major 
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co-morbidity such as heart disease or cancer was a 
strong predictor of healthcare utilization, while the 
severity of airflow obstruction as indicated by stage as 
defined by the American Thoracic Society (24) was not. 
These preliminary studies suggest that observational 
databases can provide very good information about the 
impact of COPD on healthcare costs and utilization, even 
when pulmonary function test results are not included in 
the data. 
Analysis of an administrative database has also thrown 
light on the use of inhaled corticosteroids in patients 
with COPD (26), a therapeutic approach that has 
received only ambiguous support from clinical trials 
(5,6).A database of 22 620 patients in Ontario, Canada, 
was used to identify patients aged 65 years or older 
discharged from hospital with a diagnosis of COPD.After 
adjusting for possible confounding factors, those who 
received inhaled corticosteroids within 90 days of 
discharge had 24% fewer repeat hospitalizations for 
COPD and were 29% less likely to die during the l-year 
follow-up period (Fig. 3).The association between use of 
inhaled corticosteroids and improved healthcare 
outcomes remained, irrespective of the number of co- 
morbid conditions and age. Similar results on improved 
survival with fluticasone propionate and combined 
fluticasone propionate/salmeteroI have been found from 
a study of a British hospital database (27). Clearly, analysis 
of observational databases has revealed meaningful 
results on a therapeutic approach, in a way that 
randomized controlled clinical trials have been unable to 
demonstrate unequivocally. 
CONCLUSIONS 
It is apparent that meaningful evidence on the health 
outcomes arising from different therapeutic approaches 
can be obtained from a range of sources. While 
randomized, prospective, controlled clinical trials have 
long been viewed as the ‘gold standard’ of evidence, this 
approach alone may not provide sufficient information 
from which healthcare payers can make decisions about 
resource allocation. Retrospective and observational 
studies in all-inclusive patient populations, investigating 
different therapeutic approaches within routine clinical 
care, may give data that more closely reflects the real-life 
situations of relevance to healthcare payers. Analysis of 
administrative databases may give invaluable insight into 
the health outcomes of most importance to healthcare 
payers - population-based requirement for healthcare 
services and mortality. 
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